Cargando…

Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies

Dementia with Lewy bodies (DLB) is pathologically defined by the cytoplasmic accumulation of alpha-synuclein (aSyn) within neurons in the brain. Predominately pre-synaptic, aSyn has been reported in various subcellular compartments in experimental models. Indeed, nuclear alpha-synuclein (aSyn(Nuc))...

Descripción completa

Detalles Bibliográficos
Autores principales: Koss, David J., Erskine, Daniel, Porter, Andrew, Palmoski, Pawel, Menon, Hariharan, Todd, Olivia G. J., Leite, Marta, Attems, Johannes, Outeiro, Tiago F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258129/
https://www.ncbi.nlm.nih.gov/pubmed/35794636
http://dx.doi.org/10.1186/s40478-022-01403-x
_version_ 1784741476055384064
author Koss, David J.
Erskine, Daniel
Porter, Andrew
Palmoski, Pawel
Menon, Hariharan
Todd, Olivia G. J.
Leite, Marta
Attems, Johannes
Outeiro, Tiago F.
author_facet Koss, David J.
Erskine, Daniel
Porter, Andrew
Palmoski, Pawel
Menon, Hariharan
Todd, Olivia G. J.
Leite, Marta
Attems, Johannes
Outeiro, Tiago F.
author_sort Koss, David J.
collection PubMed
description Dementia with Lewy bodies (DLB) is pathologically defined by the cytoplasmic accumulation of alpha-synuclein (aSyn) within neurons in the brain. Predominately pre-synaptic, aSyn has been reported in various subcellular compartments in experimental models. Indeed, nuclear alpha-synuclein (aSyn(Nuc)) is evident in many models, the dysregulation of which is associated with altered DNA integrity, transcription and nuclear homeostasis. However, the presence of aSyn(Nuc) in human brain cells remains controversial, yet the determination of human brain aSyn(Nuc) and its pathological modification is essential for understanding synucleinopathies. Here, using a multi-disciplinary approach employing immunohistochemistry, immunoblot, and mass-spectrometry (MS), we confirm aSyn(Nuc) in post-mortem brain tissue obtained from DLB and control cases. Highly dependent on antigen retrieval methods, in optimal conditions, intra-nuclear pan and phospho-S129 positive aSyn puncta were observed in cortical neurons and non-neuronal cells in fixed brain sections and in isolated nuclear preparations in all cases examined. Furthermore, an increase in nuclear phospho-S129 positive aSyn immunoreactivity was apparent in DLB cases compared to controls, in both neuronal and non-neuronal cell types. Our initial histological investigations identified that aSyn(Nuc) is affected by epitope unmasking methods but present under optimal conditions, and this presence was confirmed by isolation of nuclei and a combined approach of immunoblotting and mass spectrometry, where aSyn(Nuc) was approximately tenfold less abundant in the nucleus than cytoplasm. Notably, direct comparison of DLB cases to aged controls identified increased pS129 and higher molecular weight species in the nuclei of DLB cases, suggesting putative pathogenic modifications to aSyn(Nuc) in DLB. In summary, using multiple approaches we provide several lines of evidence supporting the presence of aSyn(Nuc) in autoptic human brain tissue and, notably, that it is subject to putative pathogenic modifications in DLB that may contribute to the disease phenotype. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01403-x.
format Online
Article
Text
id pubmed-9258129
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92581292022-07-07 Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies Koss, David J. Erskine, Daniel Porter, Andrew Palmoski, Pawel Menon, Hariharan Todd, Olivia G. J. Leite, Marta Attems, Johannes Outeiro, Tiago F. Acta Neuropathol Commun Research Dementia with Lewy bodies (DLB) is pathologically defined by the cytoplasmic accumulation of alpha-synuclein (aSyn) within neurons in the brain. Predominately pre-synaptic, aSyn has been reported in various subcellular compartments in experimental models. Indeed, nuclear alpha-synuclein (aSyn(Nuc)) is evident in many models, the dysregulation of which is associated with altered DNA integrity, transcription and nuclear homeostasis. However, the presence of aSyn(Nuc) in human brain cells remains controversial, yet the determination of human brain aSyn(Nuc) and its pathological modification is essential for understanding synucleinopathies. Here, using a multi-disciplinary approach employing immunohistochemistry, immunoblot, and mass-spectrometry (MS), we confirm aSyn(Nuc) in post-mortem brain tissue obtained from DLB and control cases. Highly dependent on antigen retrieval methods, in optimal conditions, intra-nuclear pan and phospho-S129 positive aSyn puncta were observed in cortical neurons and non-neuronal cells in fixed brain sections and in isolated nuclear preparations in all cases examined. Furthermore, an increase in nuclear phospho-S129 positive aSyn immunoreactivity was apparent in DLB cases compared to controls, in both neuronal and non-neuronal cell types. Our initial histological investigations identified that aSyn(Nuc) is affected by epitope unmasking methods but present under optimal conditions, and this presence was confirmed by isolation of nuclei and a combined approach of immunoblotting and mass spectrometry, where aSyn(Nuc) was approximately tenfold less abundant in the nucleus than cytoplasm. Notably, direct comparison of DLB cases to aged controls identified increased pS129 and higher molecular weight species in the nuclei of DLB cases, suggesting putative pathogenic modifications to aSyn(Nuc) in DLB. In summary, using multiple approaches we provide several lines of evidence supporting the presence of aSyn(Nuc) in autoptic human brain tissue and, notably, that it is subject to putative pathogenic modifications in DLB that may contribute to the disease phenotype. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01403-x. BioMed Central 2022-07-06 /pmc/articles/PMC9258129/ /pubmed/35794636 http://dx.doi.org/10.1186/s40478-022-01403-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Koss, David J.
Erskine, Daniel
Porter, Andrew
Palmoski, Pawel
Menon, Hariharan
Todd, Olivia G. J.
Leite, Marta
Attems, Johannes
Outeiro, Tiago F.
Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
title Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
title_full Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
title_fullStr Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
title_full_unstemmed Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
title_short Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
title_sort nuclear alpha-synuclein is present in the human brain and is modified in dementia with lewy bodies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258129/
https://www.ncbi.nlm.nih.gov/pubmed/35794636
http://dx.doi.org/10.1186/s40478-022-01403-x
work_keys_str_mv AT kossdavidj nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT erskinedaniel nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT porterandrew nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT palmoskipawel nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT menonhariharan nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT toddoliviagj nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT leitemarta nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT attemsjohannes nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies
AT outeirotiagof nuclearalphasynucleinispresentinthehumanbrainandismodifiedindementiawithlewybodies